FY2024 Earnings Estimate for ELAN Issued By Leerink Partnrs

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at Leerink Partnrs issued their FY2024 earnings estimates for shares of Elanco Animal Health in a research report issued on Monday, December 2nd. Leerink Partnrs analyst D. Clark forecasts that the company will post earnings of $0.93 per share for the year. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q4 2024 earnings at $0.16 EPS, Q1 2025 earnings at $0.32 EPS, Q2 2025 earnings at $0.28 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.89 EPS, FY2026 earnings at $0.99 EPS, FY2027 earnings at $1.19 EPS and FY2028 earnings at $1.42 EPS.

ELAN has been the subject of a number of other research reports. Morgan Stanley lowered shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Stifel Nicolaus restated a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Leerink Partners initiated coverage on shares of Elanco Animal Health in a report on Monday. They set a “market perform” rating and a $14.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $16.75.

Elanco Animal Health Stock Down 7.4 %

Elanco Animal Health stock opened at $12.48 on Wednesday. The firm has a market cap of $6.17 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 1.41 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health has a fifty-two week low of $11.40 and a fifty-two week high of $18.80. The firm has a fifty day moving average price of $13.52 and a two-hundred day moving average price of $14.55.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business’s revenue was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.18 EPS.

Hedge Funds Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. lifted its position in shares of Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in shares of Elanco Animal Health during the third quarter worth approximately $29,000. ORG Partners LLC acquired a new position in shares of Elanco Animal Health during the second quarter worth approximately $31,000. nVerses Capital LLC acquired a new position in shares of Elanco Animal Health during the second quarter worth approximately $32,000. Finally, AM Squared Ltd acquired a new position in shares of Elanco Animal Health during the third quarter worth approximately $34,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.